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Endometriosis is a debilitating disease characterized
by the growth of ectopic endometrial tissue. It is
widely accepted that angiogenesis plays an integral
part in the establishment and growth of endometri-
otic lesions. Recent data from a variety of angiogene-
sis-dependent diseases suggest a critical role of bone
marrow–derived endothelial progenitor cells (EPCs) in
neovascularization. In this study we examined the
blood levels of EPCs and mature circulating endothelial
cells in a mouse model of surgically induced endome-
triosis. Fluorescence-activated cell sorting analysis re-
vealed elevated levels of EPCs in the blood of mice with
endometriosis compared with control subject that un-
derwent a sham operation. EPC concentrations posi-
tively correlated with the amount of endometriotic tis-
sue and peaked 1 to 4 days after induction of disease. In
a green fluorescent protein bone marrow transplant
experiment we found green fluorescent protein–posi-
tive endothelial cells incorporated into endometriotic
lesions but not eutopic endometrium, as revealed by
flow cytometry and immunohistochemistry. Finally,
treatment of endometriosis-bearing mice with the an-
giogenesis inhibitor Lodamin, an oral nontoxic formu-
lation of TNP-470, significantly decreased EPC levels
while suppressing lesion growth. Taken together, our
data indicate an important role for bone marrow–
1782derived endothelial cells in the pathogenesis of endo-
metriosis and support the potential clinical use of
anti-angiogenic therapy as a novel treatment modality
for this disease. (Am J Pathol 2011, 178:1782–1791; DOI:
10.1016/j.ajpath.2010.12.037)
Endometriosis, or extra-uterine endometrial-like tissue,
affects approximately 10% of women during their repro-
ductive years.1 The disease causes debilitating pain and
severely affects quality of life with symptoms mimicking
those associated with other chronic pain disorders, such
as irritable bowel syndrome and pelvic inflammatory dis-
ease. In addition, endometriosis is closely associated
with infertility.2 The diagnosis is usually made upon visual
inspection of the pelvis during laparoscopy; noninvasive
diagnostic tools, such as ultrasound scanning, can reli-
ably detect only severe forms of the disease, such as
ovarian endometriotic cysts.3 As a result, women can
suffer for 8 to 12 years before receiving a definitive diag-
nosis and appropriate treatment.4 A biomarker of endo-
metriosis would be invaluable to aid in earlier diagnosis
and to monitor therapeutic efficacy.
The treatment options and success rates are limited,
partially because of a lack of understanding of the patho-
genesis of endometriosis. Treatments include use of hor-
monal drugs to suppress ovarian function, surgical abla-
tion of endometriotic lesions, and, if necessary, removal
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is the third-leading gynecological cause for hospitaliza-
tion and is associated with significant costs.5,6 In addi-
tion, patients with endometriosis have an increased risk
of ovarian cancer and non-Hodgkin’s lymphoma,7,8
which adds to the burden of the disease.
Although the pathogenesis of endometriosis remains
uncertain, recent studies by our group and others have
demonstrated that the development of a vascular supply
is essential for the establishment and growth of endo-
metriotic lesions.9,10 Thus inhibition of angiogenesis has
been suggested as a novel therapeutic approach11 and
has shown promise in preclinical studies.12–15 Neovas-
cularization occurs as a result of local sprouting of endo-
thelial cells, elongation of pre-existing blood vessels, or
de novo vasculogenesis.16 Elevated local or systemic
levels of angiogenic factors not only result in migration
and proliferation of endothelial cells but also recruit en-
dothelial cells from the bone marrow.17,18 Vascular endo-
thelial growth factor (VEGF), which is highly up-regulated
in endometriotic lesions, eutopic endometrium, and peri-
toneal fluid of patients with endometriosis,19–21 is a
strong stimulus for the recruitment of bone marrow–de-
rived endothelial progenitor cells (EPCs).22 Elevated
VEGF serum levels in patients with endometriosis have
been reported by some researchers23 but not by oth-
ers,24 which may be due to the short half-life of VEGF of
approximately 3 minutes.25 Considerable debate cur-
rently exists about the contribution of EPCs to neovascu-
larization of tumors. Particular interest has focused on
whether EPCs incorporate into the growing vascular tree
and, if so, to what extent they contribute to neovascular-
ization.26–29 VEGF inhibition appears to decrease levels
of EPCs and increase the detachment of mature circulat-
ing endothelial cells (CECs) originating from tumor vas-
culature.30 Thus it has been suggested that EPCs and
CECs can be used as surrogate markers for disease
progression and efficacy of anti-angiogenic therapy in
tumors.31
Endometriosis and tumor growth both require angio-
genesis for expansion of mass.10 Because previous work
has suggested the use of EPCs as an indicator of tumor
growth and regression, in this study we investigated the
role of EPCs as potential biomarkers of endometriosis.
We used an established mouse model of surgically in-
duced endometriosis to measure levels of CECs and
EPCs. Further, we used a bone marrow transplantation
model to quantify the extent of EPC incorporation into the
newly forming vasculature of growing endometriotic le-
sions. Finally, our studies assess the effect of anti-angio-
genic therapy on EPC and CEC levels.
Material and Methods
Animal Handling
All procedures were performed in the animal facility at
Children’s Hospital, Boston, MA. All animal handling and
procedures were performed in accordance with federal,
local, and institutional guidelines and were approved bythe Institutional Animal Care and Use Committee of Chil-
dren’s Hospital. Eight-week-old female 129  1/SvJ mice
were purchased from Jackson Laboratories (Bar Harbor,
MN); 129S6/SvEvTac mice were purchased from Taconic
Farms (Hudson, NY), and C57BL/6 mice were purchased
from Charles River Laboratories (Wilmington, MA).
C57BL/6J-GFP-mice were a generous gift from Dr. Taturo
Udagawa.32 The mice were caged in groups of five to 10
with free access to chow and water; they were accli-
mated for 3 weeks before any experiment. The animal
room was kept constantly at 26°C, 38.5% humidity, with a
12-hour light, 12-hour dark cycle (7:30 AM to 7:30 PM).
Mice received no hormonal treatment.
Induction of Endometriosis
Mice were randomly taken from different cages to mini-
mize any potential effects of the stage of the estrous
cycle, which was determined by vaginal smears as pre-
viously described.12 Consequently, the stages were
evenly distributed across the different groups in all ex-
periments (data not shown). All surgical procedures were
performed under inhalational anesthesia with isoflurane
(Baxter, Deerfield, IL), and mice were observed until they
fully recovered. Endometriosis was surgically induced as
described previously.33–36 Briefly, the uterine horns were
removed through a midline abdominal incision and
opened longitudinally in a Petri dish containing warmed
0.9% saline solution. Four or six biopsy specimens (2 mm
in diameter) were obtained with use of a dermal biopsy
punch (Miltex, Bethpage, NY), and the lesions were au-
totransplanted to the peritoneal wall with the endometrial
side facing the peritoneum using a braided 7–0 silk su-
ture (Ethicon, Somerville, NJ). The wound was closed
with a 5–0 suture (Ethicon). Identical procedures were
performed in the “sham group” except that sutures alone
were inserted instead of endometrial tissue. Mice in the
“control group” did not undergo surgery. For initial exper-
iments (Figure 1), blood was taken 1 week after inocula-
tion with endometriosis. For all of the other experiments,
blood was drawn and mice were sacrificed at the indi-
cated time points. At the end of the experiment, lesions
were measured at their implantation site as described
previously: two perpendicular diameters (D1, D2) of each
lesion were measured with a caliper to the nearest tenth
of a millimeter.12,37,38 Lesion volumes were determined
using the formula for a sphere (volume D1 D2 /4).
Lesions were then excised for further processing. In
some groups of mice the uteri also were removed for
further analysis (described in a later section).
Lodamin Treatment
129S6/SvEvTac mice were divided into three groups
(“endometriosis,” “sham,” and “control”; n  20/group).
Half of the mice received 15 mg/kg Lodamin, an oral
formulation of the angiogenesis inhibitor TNP-470, or ve-
hicle daily by oral gavage for 14 days.39 Mice were mon-
itored daily for changes in weight. Daily vaginal smears
were taken, and uterine horns were removed at the end of
the experiment to determine the potential effect of
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plantation experiments, C57BL/6J mice with transplanted
green fluorescent protein (GFP) bone marrow received
endometriotic tissue from wild-type C57BL/6J mice.
Bone Marrow Transplantation
Bone marrow transplantation was performed as described
previously.40 In brief, bone marrow was harvested from
C57BL/6J-GFP mice. The donor mice were euthanized us-
ing carbon dioxide, and their femurs were dissected and
then flushed with 1 mL sterile 0.9% saline solution to collect
bone marrow. Anesthetized recipient C57BL/6 mice
(Charles River Laboratories) were lethally irradiated with
950 Gy. The harvested GFP bonemarrow was then injected
into the retro-orbital plexus of into the irradiated recipients in
100 L 0.9% saline solution. The bone marrow was allowed
to engraft for 6 weeks. Engraftment was verified by GFP-
Figure 1. Blood EPC numbers in mice. Female mice received endometriotic
(black columns) or sham lesions (gray columns) during abdominal surgery or
were not operated upon (control subjects, white columns). Whole blood was
taken after 1 week and stained for EPC markers (flow cytometry). Female
C57BL/6 mice received four lesions (A) or six lesions (B) (*P  0.05; **P 
0.001, posthoc Bonferroni test). Female 129SvJ mice received six lesions (C).
All experiments were performed with n  10 per group. Values shown are
mean  SEM (*P  0.05; **P  0.007, posthoc Bonferroni test).positive blood samples before endometriosis induction.Flow Cytometry Analysis of Circulating
Endothelial Cells
Circulating EPCs and CECs were measured in the pe-
ripheral blood of all of the mice. After induction of anes-
thesia using isoflurane, 500 L to 1000 L of blood was
collected by retro-orbital puncture and anticoagulated
with use of sodium citrate. Blood was kept on ice until
processing, and 150 L of blood was used to quantify
circulating endothelial cells using four-color flow cytom-
etry as previously described.30,41,42 Red blood cells were
lysed using FACSLyse Solution (BD Biosciences, San
Jose, CA), according to the manufacturer’s directions.
For the fluorescence-activated cell sorting analysis of
GFP-positive cells in tissue, eutopic endometrium and
endometriotic lesions were taken from mice that had un-
dergone a bone marrow transplantation and wild-type
mice. Tissue was incubated in Dispase 2 (Roche, Nutley,
NJ) for 30 minutes at 37°C per the manufacturer’s instruc-
tions to dissociate tissue into single-cell suspensions,
re-suspended in Dulbecco’s modified Eagle’s medium
with 10% fetal bovine serum to neutralize enzymes, and
washed in PBS with 1% bovine serum albumin before
staining with antibodies and performing fluorescence-
activated cell sorting analysis.
The following directly conjugated antibodies were
used to detect EPCs and CECs in peripheral mouse
blood: anti-mouse CD45-PerCP, CD31-APC (platelet/en-
dothelial cell adhesion molecule-1), Flk-1-PE (mouse
VEGFR-2; all BD Biosciences, San Jose, CA), and
CD133-fluorescein isothiocyanate (Prominin-1; eBio-
science, San Diego, CA). Tissue was stained with the
same antibodies except the CD133 fluorescein isothio-
cyanate antibody. Flow cytometry was performed us-
ing a FACSCalibur flow cytometer (BD Biosciences, San
Jose, CA) and acquired data were analyzed with
FLOWJO flow cytometry analysis software (Treestar, Ash-
land, OR), with analysis gates designed to remove resid-
ual platelets and cellular debris. Fluorescence minus one
control subjects were used for gating. Between 500,000
and 1000,000 events were counted in each sample.
SV40-transformed murine endothelial (MS-1) cells43 were
spiked into blood samples as a positive control for com-
pensation and gating purposes.30
Circulating endothelial cells in mouse peripheral blood
were assessed using flow cytometry and then classified
into mature (CECs: CD45, VEGFR-2, CD31, CD133)
and bone marrow–derived progenitor endothelial cells
(EPCs: CD45, VEGFR-2, CD31, CD133) as previ-
ously described.30,41,42,44
Immunohistochemistry
Immunohistochemical staining was carried out on 8-m
frozen sections. For CD31-Cy3 staining, sections were
dried for 2 to 3 hours at room temperature and circled
with an Immedge Pen (Vector Laboratories, Burlingame,
CA). Sections were immersed in 0.3% Triton X-100 PBS
(T-PBS), washed twice with PBS, and then blocked for 1
hour with 5% goat serum (Jackson ImmunoResearch,
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bovine serum albumin  0.01% Thimerosal. The same
solution without goat serum was used to dilute antibod-
ies. Incubation with primary antibody (rat anti-mouse
CD31, 1:500, BD Biosciences) was carried out overnight.
Slides were then washed with T-PBS and incubated with
secondary antibody (Cy3-goat anti-rat 1:400, Jackson
ImmunoResearch) for 4 to 5 hours. Slides were then
washed with T-PBS and fixed with 4% paraformaldehyde
for 15 minutes. The final washes with PBS were done
before mounting with Vectashield Mounting Medium with
DAPI (Vector Laboratories) according to the manufactur-
er’s instructions.
Uterine horns and ovaries were removed from mice in
all groups after Lodamin treatment. Tissues were snap
frozen in liquid nitrogen and mounted in OCT embedding
medium (Thermo Fisher Scientific, Waltham, MA). Sec-
tions that were 5- to 7-m thick were cut on a cryostat
machine and stained with H&E.
Statistics
All statistical comparisons were done using SigmaStat
software (Aspire Software International, Leesburg, VA) as
previously described.40 The number of mature CECs and
EPCs detected in each mouse was expressed as abso-
lute number of cells per microliter of blood analyzed.
Mean CEC and EPC values were then calculated and
compared between the different groups. Means and Stu-
dent’s t-test for parametric data or median and rank-sum
test for nonparametric data were applied to compare
groups. EPCs in whole blood were compared using one-
way analysis of variance (analysis of variance) with post-
hoc testing based on the Bonferroni procedure to mini-
mize type I errors (false-positive results) due to multiple
group comparisons.45 Lesion size was compared with
use of repeated-measures analysis of variance.
Results
EPC Levels Are Elevated in a Mouse Model of
Endometriosis
To examine the levels of EPCs in a mouse model of
endometriosis, we initially measured EPC counts by flow
cytometry in C57BL/6 mice with four syngeneic endo-
metriotic lesions. As we have previously described,30
EPCs were identified by their expression of three cell
surface markers including CD31 (endothelial marker),
Flk-1 (VEGFR-2, endothelial marker), and CD133 (Prom-
inin-1, stem cell marker) and the absence of CD45 (he-
matopoietic cell marker) (see Supplemental Figure S1 at
http://ajp.amjpathol.org). To distinguish between CECs
and EPCs, further characterization was done by gating
on CD133 and CD31 expression. Similar to previous re-
ports, in a typical experiment with C57BL/6 mice we
found 0.2 to 0.5 EPC per microliter of blood and five to 10
CECs per microliter of blood.30,40 In the presence of four
and six lesions, a highly statistically significant overall
difference between the three groups was observed 1week after endometriosis surgery (four lesions: F 
51.48, P  0.0001, Figure 1A; six lesions: F  8.41, P 
0.001, Figure 1B). However, the difference between the
endometriosis and sham groups were only marginally
significant or not significant.
Because various inbred murine genetic backgrounds
have been demonstrated to have variable angiogenic
responses,31,46 we chose to examine one of the most
angiogenic strains, 129/SvJ mice. Thus we implanted six
lesions per mouse into 129/SvJ mice, which have been
shown to have baseline higher circulating EPC levels.46
Our studies demonstrated a significant overall mean dif-
ference between groups (Figure 1C) (F  7.39, P 
0.003). Statistical analysis further indicated significantly
higher circulating blood EPC levels in the endometriosis
group compared with control subjects (P  0.007) or
compared with mice that underwent a sham operation
(P  0.007) (Figure 1C). No significant difference was
detected between sham treated mice versus control sub-
jects (P  0.99).
CEC and EPC Levels Decrease Over Time
To determine whether the numbers of EPCs or CECs
fluctuated over time after the implantation of endometri-
otic lesions, mice were terminally bled on various days
after disease initiation. We found a highly significant
change in lesion area over time (F  15.78, P  0.001),
with posthoc analysis revealing a significant reduction in
the first 10 days (P  0.04) and then a dramatic increase
from day 10 to day 28 (P 0.001). We next examined the
changes in mean EPCs per microliter of whole blood
between sham and endometriosis groups at specific time
points. Our results indicated overall significantly greater
circulating EPC levels in the endometriosis group (F 
10.54, P  0.002) (Figure 2B) with significant differences
at 1 day (P  0.008), 4 days (P  0.03), and 10 days
(P  0.04) but no differences at 7 days (P  0.48), 14
days (P  0.30), or 28 days (P  0.47).
We then investigated CEC levels in mice that had en-
dometriosis versus mice that underwent a sham opera-
tion over time. Overall, significantly higher CEC levels
were found in the endometriosis group (F  4.21, P 
0.04) (Figure 2C), which was confirmed by posthoc anal-
ysis for day 1 (P  0.001), but not thereafter.
Bone Marrow-Derived Cells Incorporate into the
Vasculature of Endometriotic Implants
Endometriotic lesions were implanted into irradiated wild-
type mice transplanted with GFP-expressing bone marrow.
Endothelial cells in the circulation, in the endometriotic le-
sions, and in the uterine tissue were quantified at various
time points after surgery. Uterine tissue and endometriotic
lesions were isolated and dissociated into single cell sus-
pensions, and endothelial cells were identified using flow
cytometry by the expression of two different cell surface
markers (CD31 and VEGFR2) and exclusion of a hema-
topoietic cell surface antigen (CD45) (Figure 3A). We de-
tected a highly significant increase over time in the numbers
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sions at 21 days (F  31.97, P  0.001) but no change in
uterine tissue (F  1.73, P  0.21).
The percentage of GFP-positive bone marrow–derived
cells was significantly elevated in endometriotic lesions
after 21 days (F  30.62, P  0.001) but remained con-
stant in uterine tissue (F 0.88, P 0.48) (Figure 3B). To
determine whether GFP bone marrow–derived cells were
endothelial cells, we analyzed GFP cells that were also
VEGFR2 and CD31 positive but negative for CD45 (Fig-
ure 3C). None of these cells could be detected in the
endometriotic lesions on the day after the transplantation.
Two-way analysis of variance confirmed a highly significant
increase over time in the percentage of GFP-positive endo-
thelial cells in endometriotic tissue (F  33.06, P  0.001)
and in uterine tissue (F  21.69, P  0.003). Furthermore,
incorporation of GFP-positive cells into the vasculature of
Figure 2. Blood levels of endothelial cells over time. Whole blood was
collected from mice with six endometriotic lesions after different time points
(n  5 per time point and group). A: Following blood collection, endometri-
otic lesions were measured with a caliper using the formula of an ellipse as
previously described.12,34,37,38,77 Values shown are mean  SEM. B: EPCs
stained negative for CD45 and positive for CD31, VEGRR-2, and CD133 (*P
0.04; **P  0.008; posthoc Bonferroni test). C: CECs stained negative for
CD45 and CD133 and positive for CD31 and VEGFR-2 [endometriosis group
(black squares); sham operated group (white diamonds)] (**P  0.001;
posthoc Bonferroni test).endometriotic lesions was confirmed by immunofluores-cence with an antibody to CD31, an endothelial cell specific
marker that co-localized with GFP expression (Figure 3D).
These studies confirmed the presence of endothelial pro-
genitor cells incorporated into endometriotic lesions.
Lodamin Inhibits the Up-Regulation of EPCs
and CECs
Anti-angiogenic therapy has been shown to suppress
endometriotic growth in various mouse models.15,37,38
Lodamin is an oral nontoxic formulation of TNP-470, one
of the most potent angiogenesis inhibitors known to
date.39 Cohorts of wild-type mice were either designated
as control (untouched) or had sham surgery or endo-
metriotic lesions implanted. Mice were then treated daily
with either 15 mg/kg Lodamin or vehicle alone by oral
gavage. Weight loss among the different cohorts was not
statistically significant, indicating the lack of toxicity with
daily Lodamin treatment for 1 week (data not shown).
After 1 week of treatment, blood was drawn to measure
both CEC and EPC concentrations. Statistical analysis
indicated significantly lower CECs per microliter of whole
blood for treatment compared with vehicle in the endo-
metriosis group (P  0.02) but no significant difference
between vehicle and treatment for control (P  0.09) or
sham (P  0.21) groups (Figure 4A).
When we looked at EPCs, overall highly significant
differences were observed (F  6.72, P  0.006), with
significantly lower EPCs per microliter after treatment of
the endometriosis (P  0.001), but no significant differ-
ences in the control group (P  0.11) or the sham group
(P  0.07) (Figure 4B). This finding could indicate that
anti-angiogenic therapy with Lodamin suppresses the
mobilization of both circulating endothelial cells and en-
dothelial progenitor cells in the presence of an angiogen-
esis-dependent disease.
When the lesion size was measured after 1 week of
Lodamin treatment, results indicated a significantly
smaller lesion area in the Lodamin group compared with
vehicle (1.74 mm2 versus 1.41 mm2, F 7.99, P 0.022)
(Figure 4C).
Discussion
In the present study we show that circulating endothelial
progenitor cells are elevated in an established mouse
model of endometriosis and provide evidence that
these cells incorporate into the growing vasculature of
the endometriotic lesions. EPC up-regulation appears
to be highest during early lesion establishment, coin-
ciding with increased vascular growth as previously dem-
onstrated.38 However, treatment with the potent angio-
genesis inhibitor Lodamin resulted in a significant
inhibition of this surge of circulating EPCs and subse-
quent suppression of lesion growth. These findings imply
a potential role for EPCs in the angiogenesis-dependent
growth of endometriotic lesions and may indicate the use
of EPCs as a biomarker of disease progression and sur-
rogate marker of treatment efficacy.
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blood vessel growth for disease establishment and pro-
gression. Although the exact mechanisms are unknown,
angiogenesis has been proposed to occur in endometri-
osis through classic mechanisms such as proliferation of
endothelial and supporting cells, intussusception, and
elongation of existing blood vessels.16,47 In our current
study, we demonstrate for the first time another possible
mechanism, the incorporation of bone marrow–derived
circulating endothelial progenitor cells into the growing
vascular tree. Blood EPC levels rose within 2 days of
“disease” induction and peaked during the first 10 days,
in a manner that was inversely correlated with the size of
the lesions.
Considerable debate exists about the role of EPCs, in
particular regarding the extent and significance of their
incorporation into tumor vasculature.28,44 In our study, we
found that up to 37% of all endothelial cells in the lesions
were bone marrow–derived 1 week after transplantation.
No significant increase of general bone marrow–derived
cells in the uterus was observed during this period. How-
ever, the percentage of bone marrow–derived endothe-
lial cells did increase over time, which may be a result of
changes in the estrous cycle in these animals. Human
studies have shown higher blood EPC levels during the
follicular48 and the luteal phase,49 but in this model, we
did not see estrous cycle–related differences in blood
EPC levels (data not shown). Eggermont et al demon-
strated in a xenotransplant model that human lesions
contained murine CD31-positive cells as early as day 5
A B
D
Figure 3. Endothelial cells in endometriotic lesions. After irradiating with le
endometriotic lesions from wild-type animals were implanted into these mice
(n  5 per group and time point), digested, and single cell suspensions were
uterine tissue (white diamonds)]. A: Percentage of CD45, CD31, and VEG
all cells measured. C: Percentage of CD45, CD31, VEGFR-2, and GFP
Bonferroni test).D: Immunohistochemistry of wild-type endometriotic lesion
panel) and after staining for CD31 (Cy-3; left panel). Fluorescent confocal microsco
 50 mol/L).after implantation, peaking around day 15.50 Because
host endothelial cells invaded the interface between the
peritoneal stroma and the lesion, they suggested that the
source of the endothelial cells most likely was in the prolif-
erating surrounding blood vessels. Our data suggest that
bone marrow–derived endothelial cells may contribute to
this process of blood vessel growth, especially during
early lesion establishment.
Endometriosis is a chronic, progressive disease that
frequently presents with multiple sites of extra-uterine
tissue in the peritoneal cavity. Pro-angiogenic factors
such as VEGF, basic fibroblast growth factor, and IL-8
are elevated in endometriotic tissue, peritoneal fluid, or
serum of patients with endometriosis.21,51,52 VEGF is a
well-studied mitogen for endothelial cells and strongly
increases vascular permeability.53 It has been previously
demonstrated that VEGF plays a significant role in the
mobilization of bone marrow– derived progenitor cells for
postnatal neovascularization.22
Assuming that VEGF is one of the main stimuli for the
recruitment of EPCs in this model, our current data sup-
port our previous findings that showed high VEGF levels
in the transplanted lesions during the first week after
transplantation. This rise and subsequent fall in EPC con-
centration and VEGF expression could be explained by a
hypoxic environment after the lesions lose their blood
supply followed by a normoxic one once the lesions ac-
quire new blood vessels. In fact, we have previously
demonstrated a concomitant rise in levels of hypoxia
inducible factor-1  and its downstream target, VEGF, in
C
ses, mice received GFP/ bone marrow from donor mice. Six weeks later,
s and uterine tissue were removed at different time points from different mice
and measured using flow cytometry [endometriotic lesions (black squares);
endothelial cells of all cells were measured. B: Percentage of GFP cells of
lial cells. Values shown are mean  SEM (*P  0.003; **P  0.001; posthoc
iated mice with transplanted GFP bone marrow. GFP fluorescence (middle
 thal do
. Lesion
stained
FR-2
endothe
s in irradpy showed some co-localization of GFP and CD31 cells (right panel; bar
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tion.37 Concentrations of both molecules decline thereaf-
ter when neovascularization results in the delivery of ox-
ygen and nutrients.38,50 The small, delayed rise in blood
EPC levels in the mice that underwent a sham operation
is possibly due to wound healing in these animals. Other
factors have been shown to stimulate EPC recruitments
such as stromal cell-derived factor-1, placental growth
factor, and matrix metalloprotease-9.54–56 Interestingly,
they all have been associated with endometriosis.57–60
Blood levels of mature endothelial cells also rose in
both mice that underwent a sham operation and in mice
with endometriosis, although this effect was delayed in
the sham group. We speculate that wound healing,
mainly of the abdominal wall and uterine stump, resulted
in the shedding of these cells from the local tissue in all
animals. The fact that this phenomenon occurred earlier
in the endometriosis group supports this theory, because
transplantation increases the tissue burden undergoing
regeneration. CEC concentrations in both groups were
similar after a few days, suggesting that most of the
endothelial cells originating from the transplanted lesions
had gone.
Anti-angiogenic therapy may have a role as a novel
therapeutic approach in patients with endometriosis.9
However, potential teratogenicity and inhibitory effects on
the reproductive system demonstrated by some angio-
genesis inhibitors are posing a significant hurdle to the
clinical testing of angiogenesis inhibitors in patients withendometriosis.47,61–63 We previously demonstrated that
the endogenous angiogenesis inhibitor endostatin and
its fragment mP-1 had no negative effects on the re-
productive cycle and offspring of mice, while endo-
metriotic growth was suppressed.12,34 TNP-470, a syn-
thetic fumagillin analog, is a very powerful angiogenesis
inhibitor that has been shown to inhibit endometriotic
growth15,64,65 but that caused neurotoxicity in clinical
trials.66,67 Lodamin is an oral, nontoxic form of the fum-
agillin derivative TNP-470, which inhibits tumor growth
and angiogenesis in mice.39 Possible TNP-470 mecha-
nisms on endothelial cells include affecting the cell cycle
through p53 activation by binding to methionine amino-
peptidase (MetAP-2), preventing Rac1 activation and in-
duction of p21 (CIP/WAF).68–70
In our current study we found that Lodamin sup-
pressed the levels of EPCs in the blood of mice that had
endometriosis while inhibiting growth of endometriotic
lesions. We have seen a similar effect with caplostatin
(unpublished data), an injectable, nontoxic formulation of
TNP-470 that inhibited endometriotic growth and angio-
genesis.38 TNP-470 has been shown to inhibit VEGF-
induced endothelial cell growth, migration, and vascular
hyperpermeability.71–73 In vitro data suggest that VEGF
expression by tumor cells is inhibited by TNP-470.74 Be-
cause VEGF is considered to play a central role in bone
marrow recruitment, it is conceivable that TNP-470 treat-
ment inhibits VEGF expression in the endometriotic le-
Figure 4. Effect of antiangiogenic treatment on EPCs
and CECs. Female 129 SvJ mice underwent endometri-
osis or sham surgery or no surgery (control subjects) (n
 10 per group). Half of the mice of each group
received 15 mg/kg Lodamin (Tx; black columns), an
oral, nontoxic form of the angiogenesis inhibitor TNP-
470, over 7 days. Control subjects received vehicle (V;
white columns). Whole blood was taken at the end
of the experiment, stained for (A) CEC markers
(CD45, CD31, VEGFR-2, CD133) (*P  0.02;
two-way analysis of variance) and (B) EPC markers
(CD45, CD31, VEGFR-2, CD133) (**P  0.001;
two-way analysis of variance) and measured using
flow cytometry. C: Endometriosis-like lesions were
measuredwith a caliper using the formula of an ellipse.
Mean cross-sectional area of endometriosis-like lesions
(n 6 lesions) of mice treated with vehicle or Lodamin
(*P  0.022; repeated-measures analysis of variance).
Values shown are mean  SEM.sions, resulting in a reduced stimulus for EPC mobiliza-
EPCs in Endometriosis 1789
AJP April 2011, Vol. 178, No. 4tion.75 We have previously demonstrated that VEGF is
highly up-regulated in endometriotic tissue through hyp-
oxia inducible factor-1 .37 Therefore if the TNP-470 de-
rivative Lodamin inhibits this pathway it could explain the
effect on EPC levels in the treated animals. In fact,
Lodamin inhibits VEGF-induced angiogenesis in a mouse
corneal micropocket assay.39 Treatment with Lodamin
resulted in the arrest of the estrous cycle at metestrus
(data not shown). Therefore it is conceivable that the
potential effect of the drug on estrogen levels also may
affect EPC (and CEC levels). This question is currently
under investigation.
In summary, we demonstrate that bone marrow–de-
rived endothelial cells contribute to neovascularization in
a mouse model of endometriosis. These findings high-
light the importance of angiogenesis in the establishment
and growth of endometriotic lesions, and they also sup-
port the hypothesis that endothelial progenitor cells are
involved in the pathogenesis of the disease.76 From a
clinical perspective it will be highly interesting to investi-
gate EPC and CEC levels in women who have the dis-
ease and the effect of therapy on these levels. If circu-
lating endothelial progenitor and mature endothelial cells
are elevated in patients, they may be promising and
much needed biomarkers for both diagnosis and thera-
peutic efficacy.
Acknowledgments
We thank Kristin Johnson for her excellent work with
graphics, Dr. Taturo Udagawa for fruitful discussions and
the gift of the GFP mice, and Muna El-Kasti and Janet
Carver for their technical help.
References
1. Cramer DW, Missmer SA: The epidemiology of endometriosis. Ann
NY Acad Sci 2002, 955:11–22; discussion 34–16, 396–406
2. Bulun SE: Endometriosis. N Engl J Med 2009, 360:268–279
3. Kennedy S, Bergqvist A, Chapron C, D’Hooghe T, Dunselman G,
Greb R, Hummelshoj L, Prentice A, Saridogan E: ESHRE guideline for
the diagnosis and treatment of endometriosis. Hum Reprod 2005,
20:2698–2704
4. Kennedy S, Hadfield R, Mardon H, Barlow D: Age of onset of pain
symptoms in non-twin sisters concordant for endometriosis. Hum
Reprod 1996, 11:403–405
5. Simoens S, Hummelshoj L, D’Hooghe T: Endometriosis: cost esti-
mates and methodological perspective. Hum Reprod Update 2007,
13:395–404
6. Zhao SZ, Wong JM, Davis MB, Gersh GE, Johnson KE: The cost of
inpatient endometriosis treatment: an analysis based on the Health-
care Cost and Utilization Project Nationwide Inpatient Sample. Am J
Manag Care 1998, 4:1127–1134
7. Brinton LA, Gridley G, Persson I, Baron J, Bergqvist A: Cancer risk
after a hospital discharge diagnosis of endometriosis. Am J Obstet
Gynecol 1997, 176:572–579
8. Varma R, Rollason T, Gupta JK, Maher ER: Endometriosis and the
neoplastic process. Reproduction 2004, 127:293–304
9. Becker CM, D’Amato RJ: Angiogenesis and antiangiogenic therapy in
endometriosis. Microvasc Res 2007, 74:121–130
10. Taylor RN, Lebovic DI, Mueller MD: Angiogenic factors in endometri-
osis. Ann NY Acad Sci 2002, 955:89–100; discussion 118, 396–40611. Taylor RN, Mueller MD: Anti-angiogenic treatment of endometriosis:
biochemical aspects. Gynecol Obstet Invest 2004, 57:54–5612. Becker CM, Sampson DA, Rupnick MA, Rohan RM, Efstathiou JA,
Short SM, Taylor GA, Folkman J, D’Amato RJ: Endostatin inhibits the
growth of endometriotic lesions but does not affect fertility. Fertil Steril
2005, 84(Suppl 2):1144–1155
13. Dabrosin C, Gyorffy S, Margetts P, Ross C, Gauldie J: Therapeutic
effect of angiostatin gene transfer in a murine model of endometriosis.
Am J Pathol 2002, 161:909–918
14. Laschke MW, Elitzsch A, Vollmar B, Vajkoczy P, Menger MD: Com-
bined inhibition of vascular endothelial growth factor (VEGF), fibro-
blast growth factor and platelet-derived growth factor, but not inhibi-
tion of VEGF alone, effectively suppresses angiogenesis and vessel
maturation in endometriotic lesions. Hum Reprod 2006, 21:262–268
15. Nap AW, Griffioen AW, Dunselman GA, Bouma-Ter Steege JC, Thi-
jssen VL, Evers JL, Groothuis PG: Antiangiogenesis therapy for en-
dometriosis. J Clin Endocrinol Metab 2004, 89:1089–1095
16. Carmeliet P: Angiogenesis in life, disease and medicine. Nature
2005, 438:932–936
17. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T,
Witzenbichler B, Schatteman G, Isner JM: Isolation of putative
progenitor endothelial cells for angiogenesis. Science 1997, 275:
964–967
18. Spring H, Schuler T, Arnold B, Hammerling GJ, Ganss R: Chemokines
direct endothelial progenitors into tumor neovessels. Proc Natl Acad
Sci USA 2005, 102:18111–18116
19. Donnez J, Smoes P, Gillerot S, Casanas-Roux F, Nisolle M: Vascular
endothelial growth factor (VEGF) in endometriosis. Hum Reprod
1998, 13:1686–1690
20. McLaren J, Prentice A, Charnock-Jones DS, Smith SK: Vascular
endothelial growth factor (VEGF) concentrations are elevated in
peritoneal fluid of women with endometriosis. Hum Reprod 1996,
11:220–223
21. Shifren JL, Tseng JF, Zaloudek CJ, Ryan IP, Meng YG, Ferrara N,
Jaffe RB, Taylor RN: Ovarian steroid regulation of vascular endothelial
growth factor in the human endometrium: implications for angiogen-
esis during the menstrual cycle and in the pathogenesis of endome-
triosis. J Clin Endocrinol Metab 1996, 81:3112–3118
22. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, Inai
Y, Silver M, Isner JM: VEGF contributes to postnatal neovasculariza-
tion by mobilizing bone marrow-derived endothelial progenitor cells.
EMBO J 1999, 18:3964–3972
23. Xavier P, Belo L, Beires J, Rebelo I, Martinez-de-Oliveira J, Lunet N,
Barros H: Serum levels of VEGF and TNF-alpha and their association
with C-reactive protein in patients with endometriosis. Arch Gynecol
Obstet 2006, 273:227–231
24. Gagne D, Page M, Robitaille G, Hugo P, Gosselin D: Levels of
vascular endothelial growth factor (VEGF) in serum of patients with
endometriosis. Hum Reprod 2003, 18:1674–1680
25. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other
disease. Nat Med 1995, 1:27–31
26. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V:
Endothelial progenitor cells control the angiogenic switch in mouse
lung metastasis. Science 2008, 319:195–198
27. Kerbel RS, Benezra R, Lyden DC, Hattori K, Heissig B, Nolan DJ,
Mittal V, Shaked Y, Dias S, Bertolini F, Rafii S: Endothelial progenitor
cells are cellular hubs essential for neoangiogenesis of certain ag-
gressive adenocarcinomas and metastatic transition but not adeno-
mas. Proc Natl Acad Sci USA 2008, 105:E54; author reply E55
28. Lyden D, Hattori K, Dias S, Costa C, Blaikie P, Butros L, Chadburn A,
Heissig B, Marks W, Witte L, Wu Y, Hicklin D, Zhu Z, Hackett NR,
Crystal RG, Moore MA, Hajjar KA, Manova K, Benezra R, Rafii S:
Impaired recruitment of bone-marrow-derived endothelial and hema-
topoietic precursor cells blocks tumor angiogenesis and growth. Nat
Med 2001, 7:1194–1201
29. Purhonen S, Palm J, Rossi D, Kaskenpaa N, Rajantie I, Yla-Herttuala
S, Alitalo K, Weissman IL, Salven P: Bone marrow-derived circulating
endothelial precursors do not contribute to vascular endothelium and
are not needed for tumor growth. Proc Natl Acad Sci USA 2008,
105:6620–6625
30. Beaudry P, Force J, Naumov GN, Wang A, Baker CH, Ryan A, Soker
S, Johnson BE, Folkman J, Heymach JV: Differential effects of vas-
cular endothelial growth factor receptor-2 inhibitor ZD6474 on circu-
lating endothelial progenitors and mature circulating endothelial
cells: implications for use as a surrogate marker of antiangiogenic
activity. Clin Cancer Res 2005, 11:3514–3522
1790 Becker et al
AJP April 2011, Vol. 178, No. 431. Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K,
Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J,
Hicklin DJ, D’Amato RJ, Kerbel RS: Genetic heterogeneity of the
vasculogenic phenotype parallels angiogenesis; implications for cel-
lular surrogate marker analysis of antiangiogenesis. Cancer Cell
2005, 7:101–111
32. Udagawa T, Puder M, Wood M, Schaefer BC, D’Amato RJ: Analysis of
tumor-associated stromal cells using SCID GFP transgenic mice:
contribution of local and bone marrow-derived host cells. FASEB J
2006, 20:95–102
33. Becker CM, Sampson DA, Rupnick MA, Rohan RM, Efstathiou JA,
Short SM, Taylor GA, Folkman J, D’Amato RJ: Endostatin inhibits the
growth of endometriotic lesions but does not affect fertility. Fertil Steril
2005, 84(Suppl 2):1144–1155
34. Becker CM, Sampson DA, Short SM, Javaherian K, Folkman J,
D’Amato RJ: Short synthetic endostatin peptides inhibit endothelial
migration in vitro and endometriosis in a mouse model. Fertil Steril
2006, 85:71–77
35. Cummings AM, Metcalf JL: Induction of endometriosis in mice: a new
model sensitive to estrogen. Reprod Toxicol 1995, 9:233–238
36. Vernon MW, Wilson EA: Studies on the surgical induction of endome-
triosis in the rat. Fertil Steril 1985, 44:684–694
37. Becker CM, Rohwer N, Funakoshi T, Cramer T, Bernhardt W, Birsner
A, Folkman J, D’Amato RJ: 2-Methoxyestradiol inhibits hypoxia-induc-
ible factor-1{alpha} and suppresses growth of lesions in a mouse
model of endometriosis, Am J Pathol 2008, 172:534–544
38. Becker CM, Wright RD, Satchi-Fainaro R, Funakoshi T, Folkman J,
Kung AL, D’Amato RJ: A novel noninvasive model of endometriosis
for monitoring the efficacy of antiangiogenic therapy. Am J Pathol
2006, 168:2074–2084
39. Benny O, Fainaru O, Adini A, Cassiola F, Bazinet L, Adini I, Pravda E,
Nahmias Y, Koirala S, Corfas G, D’Amato RJ, Folkman J: An orally
delivered small-molecule formulation with antiangiogenic and anti-
cancer activity. Nature Biotechnol 2008, 26:799–807
40. Beaudry P, Hida Y, Udagawa T, Alwayn IP, Greene AK, Arsenault D,
Folkman J, Heymach JV, Ryeom S, Puder M: Endothelial progenitor
cells contribute to accelerated liver regeneration. J Pediatr Surg
2007, 42:1190–1198
41. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y,
Kerbel RS: Maximum tolerable dose and low-dose metronomic
chemotherapy have opposite effects on the mobilization and via-
bility of circulating endothelial progenitor cells. Cancer Res 2003,
63:4342–4346
42. Schuch G, Heymach JV, Nomi M, Machluf M, Force J, Atala A, Eder
JP Jr, Folkman J, Soker S: Endostatin inhibits the vascular endothelial
growth factor-induced mobilization of endothelial progenitor cells.
Cancer Res 2003, 63:8345–8350
43. Arbiser JL, Moses MA, Fernandez CA, Ghiso N, Cao Y, Klauber N,
Frank D, Brownlee M, Flynn E, Parangi S, Byers HR, Folkman J:
Oncogenic H-ras stimulates tumor angiogenesis by two distinct path-
ways. Proc Natl Acad Sci USA 1997, 94:861–866
44. Bertolini F, Shaked Y, Mancuso P, Kerbel RS: The multifaceted cir-
culating endothelial cell in cancer: towards marker and target iden-
tification. Nat Rev Cancer 2006, 6:835–845
45. Cabral HJ: Multiple comparisons procedures. Circulation 2008, 117:
698–701
46. Rohan RM, Fernandez A, Udagawa T, Yuan J, D’Amato RJ: Genetic
heterogeneity of angiogenesis in mice. FASEB J 2000, 14:871–876
47. Taylor RN, Yu J, Torres PB, Schickedanz AC, Park JK, Mueller MD,
Sidell N: Mechanistic and therapeutic implications of angiogenesis in
endometriosis. Reprod Sci 2009, 16:140–146
48. Robb AO, Mills NL, Smith IB, Short A, Tura-Ceide O, Barclay GR,
Blomberg A, Critchley HO, Newby DE, Denison FC: Influence of
menstrual cycle on circulating endothelial progenitor cells. Hum Re-
prod 2009, 24:619–625
49. Matsubara K, Abe E, Matsubara Y, Kameda K, Ito M: Circulating
endothelial progenitor cells during normal pregnancy and pre-ec-
lampsia. Am J Reprod Immunol 2006, 56:79–85
50. Eggermont J, Donnez J, Casanas-Roux F, Scholtes H, Van Langen-
donckt A: Time course of pelvic endometriotic lesion revasculariza-
tion in a nude mouse model. Fertil Steril 2005, 84:492–499
51. Bourlev V, Larsson A, Olovsson M: Elevated levels of fibroblast
growth factor-2 in serum from women with endometriosis. Am J
Obstet Gynecol 2006, 194:755–75952. Ryan IP, Tseng JF, Schriock ED, Khorram O, Landers DV, Taylor RN:
Interleukin-8 concentrations are elevated in peritoneal fluid of women
with endometriosis. Fertil Steril 1995, 63:929–932
53. Benjamin LE: The controls of microvascular survival. Cancer Metas-
tasis Rev 2000, 19:75–81
54. Hattori K, Heissig B, Wu Y, Dias S, Tejada R, Ferris B, Hicklin DJ, Zhu
Z, Bohlen P, Witte L, Hendrikx J, Hackett NR, Crystal RG, Moore MA,
Werb Z, Lyden D, Rafii S: Placental growth factor reconstitutes he-
matopoiesis by recruiting VEGFR1() stem cells from bone-marrow
microenvironment. Nat Med 2002, 8:841–849
55. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett NR, Crystal
RG, Besmer P, Lyden D, Moore MA, Werb Z, Rafii S: Recruitment of
stem and progenitor cells from the bone marrow niche requires
MMP-9 mediated release of kit-ligand. Cell 2002, 109:625–637
56. Yamaguchi J, Kusano KF, Masuo O, Kawamoto A, Silver M,
Murasawa S, Bosch-Marce M, Masuda H, Losordo DW, Isner JM,
Asahara T: Stromal cell-derived factor-1 effects on ex vivo expanded
endothelial progenitor cell recruitment for ischemic neovasculariza-
tion. Circulation 2003, 107:1322–1328
57. Becker CM, Louis G, Exarhopoulos A, Mechsner S, Ebert AD, Zura-
kowski D, Moses MA: Matrix metalloproteinases are elevated in the
urine of endometriosis patients. Fertil Steril 2010, 94:2343–2346
58. Chung HW, Lee JY, Moon HS, Hur SE, Park MH, Wen Y, Polan ML:
Matrix metalloproteinase-2, membranous type 1 matrix metalloprotei-
nase, and tissue inhibitor of metalloproteinase-2 expression in ecto-
pic and eutopic endometrium. Fertil Steril 2002, 78:787–795
59. Furuya M, Suyama T, Usui H, Kasuya Y, Nishiyama M, Tanaka N,
Ishiwata I, Nagai Y, Shozu M, Kimura S: Up-regulation of CXC chemo-
kines and their receptors: implications for proinflammatory microen-
vironments of ovarian carcinomas and endometriosis. Hum Pathol
2007, 38:1676–1687
60. Suzumori N, Sugiura-Ogasawara M, Katano K, Suzumori K: Women
with endometriosis have increased levels of placental growth factor in
the peritoneal fluid compared with women with cystadenomas. Hum
Reprod 2003, 18:2595–2598
61. D’Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an
inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994, 91:4082–4085
62. Klauber N, Rohan RM, Flynn E, D’Amato RJ: Critical components of
the female reproductive pathway are suppressed by the angiogene-
sis inhibitor AGM-1470. Nat Med 1997, 3:443–446
63. Van Langendonckt A, Donnez J, Defrere S, Dunselman GA, Groothuis
PG: Antiangiogenic and vascular-disrupting agents in endometriosis:
pitfalls and promises. Mol Hum Reprod 2008, 14:259–268
64. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H,
Folkman J: Synthetic analogues of fumagillin that inhibit angiogenesis
and suppress tumour growth. Nature 1990, 348:555–557
65. Nap AW, Dunselman GA, Griffioen AW, Mayo KH, Evers JL, Groothuis
PG: Angiostatic agents prevent the development of endometriosis-
like lesions in the chicken chorioallantoic membrane. Fertil Steril
2005, 83:793–795
66. Bhargava P, Marshall JL, Rizvi N, Dahut W, Yoe J, Figuera M, Phipps
K, Ong VS, Kato A, Hawkins MJ: A Phase I and pharmacokinetic
study of TNP-470 administered weekly to patients with advanced
cancer. Clin Cancer Res 1999, 5:1989–1995
67. Herbst RS, Madden TL, Tran HT, Blumenschein GR, Jr., Meyers CA,
Seabrooke LF, Khuri FR, Puduvalli VK, Allgood V, Fritsche HA, Jr.,
Hinton L, Newman RA, Crane EA, Fossella FV, Dordal M, Goodin T,
Hong WK: Safety and pharmacokinetic effects of TNP-470, an angio-
genesis inhibitor, combined with paclitaxel in patients with solid
tumors: evidence for activity in non-small-cell lung cancer. J Clin
Oncol 2002, 20:4440–4447
68. Nahari D, Satchi-Fainaro R, Chen M, Mitchell I, Task LB, Liu Z,
Kihneman J, Carroll AB, Terada LS, Nwariaku FE: Tumor cytotoxicity
and endothelial Rac inhibition induced by TNP-470 in anaplastic
thyroid cancer. Mol Cancer Ther 2007, 6:1329–1337
69. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM: The
anti-angiogenic agent fumagillin covalently binds and inhibits the
methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 1997,
94:6099–6103
70. Zhang Y, Griffith EC, Sage J, Jacks T, Liu JO: Cell cycle inhibition by
the anti-angiogenic agent TNP-470 is mediated by p53 and
p21WAF1/CIP1. Proc Natl Acad Sci USA 2000, 97:6427–6432
EPCs in Endometriosis 1791
AJP April 2011, Vol. 178, No. 471. Kusaka M, Sudo K, Matsutani E, Kozai Y, Marui S, Fujita T, Ingber D,
Folkman J: Cytostatic inhibition of endothelial cell growth by the angiogen-
esis inhibitor TNP-470 (AGM-1470). Br J Cancer 1994, 69:212–216
72. Satchi-Fainaro R, Mamluk R, Wang L, Short SM, Nagy JA, Feng D,
Dvorak AM, Dvorak HF, Puder M, Mukhopadhyay D, Folkman J: Inhibi-
tion of vessel permeability by TNP-470 and its polymer conjugate, ca-
plostatin. Cancer Cell 2005, 7:251–261
73. Yoshida A, Anand-Apte B, Zetter BR: Differential endothelial migration
and proliferation to basic fibroblast growth factor and vascular endothe-
lial growth factor. Growth Factors 1996, 13:57–6474. Kaya M, Wada T, Nagoya S, Kawaguchi S, Yamashita T,
Yamamoto N, Yoshimoto M, Okada F, Ishii S: TNP-470 Suppressesthe tumorigenicity of HT1080 fibrosarcoma tumor through the
inhibition of VEGF secretion from the tumor cells. Sarcoma 2001,
5:197–202
75. Khakoo AY, Finkel T: Endothelial progenitor cells. Annu Rev Med
2005, 56:79–101
76. Gargett CE: Uterine stem cells: what is the evidence?. Hum Reprod
Update 2007, 13:87–101
77. Efstathiou JA, Sampson DA, Levine Z, Rohan RM, Zurakowski D,
Folkman J, D’Amato RJ, Rupnick MA: Nonsteroidal antiinflamma-
tory drugs differentially suppress endometriosis in a murine model.
Fertil Steril 2005, 83:171–181
